Dr. O'Regan on Biomarker Research in Breast Cancer

Ruth O'Regan, MD
Published: Thursday, Oct 26, 2017



Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.

Molecular assays are used to make decisions of whether to give chemotherapy to patients or for prognostic reasons. According to O’Regan, it would interesting to use one of the existing assays, such as 21-Gene Recurrence Score, to determine which patients need a more intensive treatment.

Currently, no RNA has been extracted but that is something that could make sense as a biomarker for these patients.
 


Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.

Molecular assays are used to make decisions of whether to give chemotherapy to patients or for prognostic reasons. According to O’Regan, it would interesting to use one of the existing assays, such as 21-Gene Recurrence Score, to determine which patients need a more intensive treatment.

Currently, no RNA has been extracted but that is something that could make sense as a biomarker for these patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x